Anastasia G. Eleftheraki

Anastasia G. Eleftheraki

Auto-generated profile, based on publicly available information

Anastasia G. Eleftheraki

Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Annals of Oncology
Verified
Journal Article
Closed access
George FountzilasGeorge Fountzilas
George Fountzilas
TCTudor Eliade Ciuleanu
Tudor Eliade Ciuleanu
MBMattheos Bobos
Mattheos Bobos
AKA. Kalogera-Fountzila
A. Kalogera-Fountzila
AEA.G. Eleftheraki
A.G. Eleftheraki
TCT. Ciuleanu
T. Ciuleanu
Concomitant administration of radiation therapy (RT) and chemotherapy with cisplatin (CCRT) is considered standard treatment in patients with locally advanced nasopharyngeal cancer (LA-NPC). The role of induction chemotherapy (IC) when followed by CCRT in improving locoregional control remains controversial. Totally, 141 eligible patients with LA-NPC were randomized to either three cycles of IC with cisplatin 75 mg/m(2), epirubicin 75 mg/m(2) and paclitaxel (Taxol) 175 mg/m(2) (CEP) every 3 weeks followed by definitive RT (70 Gy) and concomitant weekly infusion of cisplatin 40 mg/m(2) (investigational arm, 72 patients) or to the same CCRT regimen alone (control arm, 69 patients). Sixty-two patients (86%) received three cycles of IC. No difference between the arms was observed in the number of patients who completed RT (61 versus 64, P = 018). Overall and complete response rates were very similar in the two arms and so were 3-year progression-free and overall survival rates. Grade III or IV toxic effects from IC were infrequent, apart of alopecia. Mucositis, weight loss and leukopenia were the most prominent side-effects from CCRT. IC with three cycles of CEP when followed by CCRT did not significantly improve response rates and/or survival compared with that of CCRT alone.

19 May 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ERE. Razis
E. Razis
MBMattheos Bobos
Mattheos Bobos
VKV. Kotoula
V. Kotoula
AEA. G. Eleftheraki
A. G. Eleftheraki
HKH. P. Kalofonos
H. P. Kalofonos
GFG. Fountzilas
G. Fountzilas

7 November 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
Aristotle BamiasAristotle Bamias
Aristotle Bamias
UDU. Dafni
U. Dafni
AKA. Karadimou
A. Karadimou
ETE. Timotheadou
E. Timotheadou
GAGerasimos Aravantinos
Gerasimos Aravantinos
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
The combinations of methotrexate, vinblastine, Adriamycin, cisplatin (Pharmanell, Athens, Greece) (MVAC) or gemcitabine, cisplatin (GC) represent the standard treatment of advanced urothelial cancer (UC). Dose-dense (DD)-MVAC has achieved longer progression-free survival (PFS) than the conventional MVAC. However, the role of GC intensification has not been studied. We conducted a randomized, phase III study comparing a DD-GC regimen with DD-MVAC in advanced UC. One hundred and thirty patients were randomly assigned between DD-MVAC: 66 (M 30 mg/m2, V 3 mg/m2, A 30 mg/m2, C 70 mg/m2 q 2 weeks) and DD-GC 64 (G 2500 mg/m2, C 70 mg/m2 q 2 weeks). The median follow-up was 52.1 months (89 events). The median overall survival (OS) and PFS were 19 and 8.5 months for DD-MVAC and 18 and 7.8 months for DD-GC (P = 0.98 and 0.36, respectively). Neutropenic infections were less frequent for DD-GC than for DD-MVAC (0% versus 8%). More patients on DD-GC received at least six cycles of treatment (85% versus 63%, P = 0.011) and the discontinuation rate was lower for DD-GC (3% versus 13%). Although DD-GC was not superior to DD-MVAC, it was better tolerated. DD-GC could be considered as a reasonable therapeutic option for further study in this patient population. ACTRN12610000845033, www.anzctr.org.au.

3 January 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GIGeorgios Iliadis
Georgios Iliadis
VKVassiliki Kotoula
Vassiliki Kotoula
ACAthanasios Chatzisotiriou
Athanasios Chatzisotiriou
DTDespina Televantou
Despina Televantou
AEAnastasia G Eleftheraki
Anastasia G Eleftheraki
George FountzilasGeorge Fountzilas
George Fountzilas
In this study several tumor-related volumes were assessed by means of a computer-based application and a survival analysis was conducted to evaluate the prognostic significance of pre- and postoperative volumetric data in patients harboring glioblastomas. In addition, MGMT (O6-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development.

14 November 2009 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
UDU. Dafni
U. Dafni
IGI. Grimani
I. Grimani
AXA. Xyrafas
A. Xyrafas
AEA. G. Eleftheraki
A. G. Eleftheraki
GFG. Fountzilas
G. Fountzilas

9 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EFElena Fountzilas
Elena Fountzilas
VKVassiliki Kotoula
Vassiliki Kotoula
NANikolaos Angouridakis
Nikolaos Angouridakis
IKIlias Karasmanis
Ilias Karasmanis
RWRalph M. Wirtz
Ralph M. Wirtz
George FountzilasGeorge Fountzilas
George Fountzilas
Local recurrence is the major manifestation of treatment failure in patients with operable laryngeal carcinoma. Established clinicopathological factors cannot sufficiently predict patients that are likely to recur after treatment. Additional tools are therefore required to accurately identify patients at high risk for recurrence. This study attempts to identify and independently validate gene expression models, prognostic of disease-free survival (DFS) in operable laryngeal cancer. Using Affymetrix U133A Genechips, we profiled fresh-frozen tumor tissues from 66 patients with laryngeal cancer treated locally with surgery. We applied Cox regression proportional hazards modeling to identify multigene predictors of recurrence. Gene models were then validated in two independent cohorts of 54 and 187 patients (fresh-frozen and formalin-fixed tissue validation sets, respectively). We focused on genes univariately associated with DFS (p<0.01) in the training set. Among several models comprising different numbers of genes, a 30-probe set model demonstrated optimal performance in both the training (log-rank, p<0.001) and 1st validation (p = 0.010) sets. Specifically, in the 1st validation set, median DFS as predicted by the 30-probe set model, was 34 and 80 months for high- and low-risk patients, respectively. Hazard ratio (HR) for recurrence in the high-risk group was 3.87 (95% CI 1.28–11.73, Wald's p = 0.017). Testing the expression of selected genes from the above model in the 2nd validation set, with qPCR, revealed significant associations of single markers, such as ACE2, FLOT1 and PRKD1, with patient DFS. High PRKD1 remained an unfavorable prognostic marker upon multivariate analysis (HR = 2.00, 95% CI 1.28–3.14, p = 0.002) along with positive nodal status. We have established and validated gene models that can successfully stratify patients with laryngeal cancer, based on their risk for recurrence. It seems worthy to prospectively validate PRKD1 expression as a laryngeal cancer prognostic marker, for routine clinical applications.